Discovery of Potent Protease Inhibitors for Covid-19 Treatment using Specifically Designed Novel bis-amide Derivatives

Researchers at Purdue University have developed potent inhibitors for the SARS-CoV-2 protease enzyme 3CLpro. Covid-19, an infection caused by the SARS-CoV-2 virus, has led to an ongoing global pandemic. Currently, no effective drug treatment is available for Covid-19. To find a potential therapeutic for Covid-19, Purdue researchers discovered a series of novel noncovalent functionalized bis-amide derivatives that were previously reported to inhibit a SARS-CoV-2 enzyme, 3CLpro. These are modified versions of previous compounds to improve drug-like characteristics and antiviral properties against SARS-CoV-2. The inhibitors have been evaluated in immunocytochemical and cellular assays against Covid-19 infections. These compounds show promise to be an effective treatment for Covid-19 upon further evaluation on in vivo systems.

Advantages:

-Potent Covid-19 Antiviral Properties

-Improved Drug-Like Features

Potential Applications:

-Covid-19 Treatment

-Pandemic Control

-Pharmaceutical Research and Development

Technology Validation: The bis-amide compounds potently inhibited SARS-CoV-2 in in vitro studies and immunocytochemistry assays.

TRL: 3

Intellectual Property:

Keywords: SARS-CoV-2, protease enzyme 3CLpro, potent inhibitors, Covid-19, antiviral properties, noncovalent, bis-amide derivatives, drug-like features, pharmaceutical research, pandemic control